(SeeNews) - Apr 17, 2013 - Belgian biotechnology firm Galapagos (EBR:GLPG) said Tuesday it would receive an additional payment of USD 20 million (EUR 15.2m) from its US partner AbbVie (NYSE:ABBV).
Galapagos will get the funding because of expanding the Phase IIb programme with GLPG0634 in rheumatoid arthritis (RA). The number of patients enrolled will be increased to 875.
SeeNews Belgium, "Galapagos to secure USD-20m payment from AbbVie."
No comments:
Post a Comment